A5045842108- Influenza Virus Research Studies
- Respiratory viral infections research
- SARS-CoV-2 and COVID-19 Research
- COVID-19 epidemiological studies
- Viral Infections and Outbreaks Research
- Acute Myeloid Leukemia Research
- Immune Response and Inflammation
- Animal Disease Management and Epidemiology
- Chronic Myeloid Leukemia Treatments
- Vaccine Coverage and Hesitancy
- RNA modifications and cancer
- Microbial Inactivation Methods
- Gastrointestinal Tumor Research and Treatment
- Pancreatic and Hepatic Oncology Research
- Lymphoma Diagnosis and Treatment
- Platelet Disorders and Treatments
- Neuroendocrine Tumor Research Advances
- Renal Diseases and Glomerulopathies
- Complement system in diseases
- DNA and Nucleic Acid Chemistry
- Viral gastroenteritis research and epidemiology
- Immunodeficiency and Autoimmune Disorders
- Mycobacterium research and diagnosis
- Electromagnetic Fields and Biological Effects
- Effects of Radiation Exposure
World Health Organization
2011-2020
Sapienza University of Rome
2000
Vaccines will be an important element in mitigating the impact of influenza pandemic. While research towards developing universal vaccines is ongoing, current strategy for vaccine supply a pandemic relies on seasonal production to switched over vaccines. Understanding how much could produced, which regions world and what timeframe critical informing preparedness. Through Global Action Plan Influenza Vaccines, 2006-2016, WHO promoted increase capacity monitors landscape through periodically...
A global shortage and inequitable access to influenza vaccines has been cause for concern developing countries who face dire consequences in the event of a pandemic. The Global Action Plan Influenza Vaccines (GAP) was launched 2006 increase capacity vaccine production address these concerns. It is widely recognized that well-developed infrastructure produce seasonal leads increased pandemic vaccines. This article summarizes results survey administered 44 manufacturers assess their...
In high-income countries, there is an increased tendency to replace inactivated seasonal trivalent influenza (TIV) vaccines with quadrivalent (QIV) as these are considered give a greater public health benefit. addition, several recent studies from the USA and Europe indicate that replacement QIV might also be cost-effective; however, situation in low- middle-income countries (LMIC) less clear few have investigated this aspect. The paper by de Boer et al. (2008) describes dynamic modelling...
The majority of seasonal influenza vaccines are trivalent, containing two A virus strains (H1N1 and H3N2) one B strain. co-circulation distinct lineages viruses can lead to mismatch between the strain recommended for trivalent vaccine circulating virus. This has led some manufacturers produce quadrivalent from each lineage in addition H1N1 H3N2 strains. However, it is also important know whether a single provide cross-protectivity against antigenically lineage. aim this study was assess...
Background. Currently, two genetic lineages of influenza B virus, B/Victoria and B/Yamagata, are cocirculating in humans various countries. This situation has raised a question regarding the possibility cross-protection between components live attenuated vaccine (LAIV) belonging to different lineages. study aimed assess naïve ferrets potential protective activity monovalent B-LAIVs against challenge with homologous heterologous wild-type (WT) viruses. Methods. Groups seronegative female 5-6...
Influenza H7N9 virus is a potentially pandemic subtype to which most people are immunologically naïve. To be better prepared for the potential occurrence of an pandemic, in 2017 World Health Organization recommended developing candidate vaccine viruses from two new viruses, A/Guangdong/17SF003/2016 (A/GD) and A/Hong Kong/125/2017 (A/HK). This report describes development live attenuated influenza (LAIV) candidates against A/GD A/HK study their safety immunogenicity ferret model order choose...
Ten years after the launch of Global Action Plan for Influenza Vaccines (GAP), World Health Organization (WHO) surveyed stakeholders to understand their perceptions what programme had achieved. This article provides a summary findings; full report will be available on-line on GAP website in November 2016 (http://www.who.int/influenza_vaccines_plan/en/). Seventy-seven responses were received from including medical doctors, national influenza center officials, country immunization teams,...
This study describes a double-blind randomized placebo-controlled phase I clinical trial in healthy adults of new potential pandemic H7N9 live attenuated influenza vaccine (LAIV) based on the human virus Yangtze River Delta hemagglutinin lineage (ClinicalTrials.gov Identifier: NCT03739229). Two doses LAIV or placebo were administered intranasally to 30 and 10 subjects, respectively. The was well-tolerated not associated with increased rates adverse events any serious events. Vaccine detected...
This study was a phase I double-blind, randomized, placebo-controlled trial to evaluate the safety and immunogenicity of Serbian-produced seasonal trivalent split, inactivated influenza vaccine in healthy adults. The manufactured eggs by Torlak Institute Virology, Vaccines Sera, Belgrade, Serbia contained A/H1N1, A/H3N2 B viruses. clinical took place at Clinical Center Belgrade. Sixty volunteers, aged 18-45 years, were enrolled trial. On day immunization, volunteers randomly assigned receive...
This study was a phase III, multicenter, double-blind, randomized, placebo-controlled trial to evaluate the safety and immunogenicity of seasonal trivalent split, inactivated influenza vaccine (TIV) in healthy Serbian adults between ages 18 65 years. egg-based manufactured by Institute Virology, Vaccines Sera, Torlak, Belgrade, Serbia. A total 480 participants were assigned randomly ratio 2:1 receive single intramuscular dose (0.5 ml) (15 µg hemagglutinin per strain) or placebo...